82 results
424B3
RGBP
Regen BioPharma Inc
24 Apr 24
Prospectus supplement
1:28pm
Months Ended
March 31, 2024
Six Months Ended
March 31, 2023
REVENUES
Revenues, Related Party
TOTAL REVENUES
COST AND EXPENSES
Research and Development … for the same period ended 2023. The disparity in Operating Losses is primarily attributable to greater Research and Development and Consulting Expenses
424B3
RGBP
Regen BioPharma Inc
19 Jan 24
Prospectus supplement
1:29pm
REVENUES
COST AND EXPENSES
Research and Development
General and Administrative
Consulting and Professional Fees
Rent
Total Costs and Expenses
OPERATING … to greater Research and Development and Consulting Expenses recognized during the quarter ended December 31, 2023 as compared to the same quarter ended 2022
424B3
RGBP
Regen BioPharma Inc
20 Nov 23
Prospectus supplement
9:38am
of research and development programs
the operation of our business; and
general economic conditions
These forward-looking statements speak only … to perform this clinical testing can far exceed the time and expense of the research and development initially required to create the product. No action can
424B3
ofk5c uy6u
2 Oct 23
Prospectus supplement
1:42pm
424B3
tpd6tcp 497l9e5t
15 May 23
Prospectus supplement
10:25am